Trulieve Cannabis (OTCMKTS:TCNNF – Get Free Report) had its target price decreased by investment analysts at Needham & Company LLC from $9.00 to $6.50 in a research report issued on Thursday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Needham & Company LLC’s target price would suggest a potential upside of 20.37% from the company’s previous close.
Other research analysts have also recently issued reports about the stock. Wedbush dropped their target price on shares of Trulieve Cannabis from $8.00 to $6.00 and set an “outperform” rating on the stock in a research note on Friday, August 11th. Stifel Nicolaus boosted their target price on shares of Trulieve Cannabis from C$8.00 to C$9.00 in a research note on Thursday, August 10th.
Trulieve Cannabis Stock Performance
Trulieve Cannabis Company Profile
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, as well as through home delivery. It produces flowers, edibles, vaporizer cartridge, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays under the Avenue, Cultivar Collection, Muse, Modern Flower, Alchemy, Momenta, Sweet Talk, Co2lors, Loveli, and Roll One brands.
- Five stocks we like better than Trulieve Cannabis
- How to Find Undervalued Stocks
- Data giants MongoDB and Snowflake just got upgraded
- Best Aerospace Stocks Investing
- Plug Power at tipping point; it’s make or break time for hydrogen
- Dividend Tax Calculator
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.